|
 |
Selected Literature on Non-antibacterial Activity of Tetracyclines
1. Amin, A.R., M.G. Attur, G.D. Thakker, P.D. Patel, P.R. Vyas, R.N. Patel, I.R. Patel, and S.B. Abramson, A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A, 1996. 93(24): p. 14014-9.
2. Golub, L.M., H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res, 1998. 12(2): p. 12-26.
3. Patel, R.N., M.G. Attur, M.N. Dave, I.V. Patel, S.A. Stuchin, S.B. Abramson, and A.R. Amin, A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production. J Immunol, 1999. 163(6): p. 3459-67.
4. Greenwald, R. and L. Golub, Biologic properties of non-antibiotic, chemically modified tetracyclines (CMTs): a structured, annotated bibliography. Curr Med Chem, 2001. 8(3): p. 237-42.
5. Akamatsu, H., Y. Niwa, I. Kurokawa, R. Masuda, S. Nishijima, and Y. Asada, Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism. Arch Dermatol Res, 1991. 283(8): p. 524-8.
6. Golub, L.M., H.M. Lee, R.A. Greenwald, M.E. Ryan, T. Sorsa, T. Salo, and W.V. Giannobile, A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res, 1997. 46(8): p. 310-9.
7. Langevitz, P., A. Livneh, I. Bank, and M. Pras, Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf, 2000. 22(5): p. 405-14.
8. Bednar, M.M. and C.E. Gross, Antiplatelet therapy in acute cerebral ischemia. Stroke, 1999. 30(4): p. 887-93.
9. Steiner, T., E. Bluhmki, M. Kaste, D. Toni, P. Trouillas, R. von Kummer, and W. Hacke, The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis, 1998. 8(4): p. 198-203.
10. Dyken, M.L., Antiplatelet agents and stroke prevention. Semin Neurol, 1998. 18(4): p. 441-50.
11. Yrjanheikki, J., R. Keinanen, M. Pellikka, T. Hokfelt, and J. Koistinaho, Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15769-74.
12. Yrjanheikki, J., T. Tikka, R. Keinanen, G. Goldsteins, P.H. Chan, and J. Koistinaho, A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A, 1999. 96(23): p. 13496-500.
13. Tikka, T.M. and J.E. Koistinaho, Minocycline provides neuroprotection against n-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol, 2001. 166(12): p. 7527-33.
14. Tikka, T., B.L. Fiebich, G. Goldsteins, R. Keinanen, and J. Koistinaho, Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci, 2001. 21(8): p. 2580-8.
15. Chen, C.C. and J.K. Wang, p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol, 1999. 55(3): p. 481-8.
16. Lee, J.C., J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, and et al., A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994. 372(6508): p. 739-46.
17. Cheung, P.Y., G. Sawicki, M. Wozniak, W. Wang, M.W. Radomski, and R. Schulz, Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation, 2000. 101(15): p. 1833-9.
18. Popovic, N., A. Schubart, B.D. Goetz, S.C. Zhang, C. Linington, and I.D. Duncan, Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol, 2002. 51(2): p. 215-23.
19. Brundula, V., N.B. Rewcastle, L.M. Metz, C.C. Bernard, and V.W. Yong, Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain, 2002. 125(Pt 6): p. 1297-308.
20. Curci, J.A., D. Mao, D.G. Bohner, B.T. Allen, B.G. Rubin, J.M. Reilly, G.A. Sicard, and R.W. Thompson, Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg, 2000. 31(2): p. 325-42.
21. Thompson, R.W. and B.T. Baxter, MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci, 1999. 878: p. 159-78.
22. Bendeck, M.P., M. Conte, M. Zhang, N. Nili, B.H. Strauss, and S.M. Farwell, Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol, 2002. 160(3): p. 1089-95.
23. Study reveals Periostat lowers C-reactive protein in patients suffering from acute coronary syndromes. Dent Today, 2003. 22(1): p. 24, 26.
24. Mosorin, M., J. Juvonen, F. Biancari, J. Satta, H.M. Surcel, M. Leinonen, P. Saikku, and T. Juvonen, Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg, 2001. 34(4): p. 606-10.
25. Nelissen, I., E. Martens, P.E Van den Steen, P. Proost, I. Ronsse, and G. Opdenakker, Gelatinase B/Matrix Metalloprotease-9 cleaves Interferon-B and is a target for immunotherapy. Brain, 2003. 126: p. 1371-1382.
26. Metz, L.M., Zhang, Y., Yeung, M., Patry, D.G., Bell, R.B., Stoian, C.A., Yong, V.W., Patten, S.B., Duquette, P., Antel, J.P., and Mitchell, J.R., Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesion in multiple sclerosis. Ann.Neurol, 2004. 55(5): p. 756.
|
